Caplin Point gains as its arm gets USFDA`s approval for Calcium Gluconate Injection
Caplin Point Laboratories is currently trading at Rs. 1738.60, up by 2.70 points or 0.16% from its previous closing of Rs. 1735.90 on the BSE.
The scrip opened at Rs. 1735.05 and has touched a high and low of Rs. 1774.25 and Rs. 1728.05 respectively. So far 5958 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2396.95 on 17-Sep-2025 and a 52 week low of Rs. 1502.45 on 30-Mar-2026.
Last one week high and low of the scrip stood at Rs. 1766.55 and Rs. 1679.00 respectively. The current market cap of the company is Rs. 13183.47 crore.
The promoters holding in the company stood at 70.57%, while Institutions and Non-Institutions held 8.29% and 21.14% respectively.
Caplin Point Laboratories’ subsidiary -- Caplin Steriles (CSL) has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Calcium Gluconate Injection USP (100 mg/mL in 10 mL, 50 mL and 100 mL Vials), a generic therapeutic equivalent version of the Reference Listed Drug (RLD) from Fresenius Kabi USA, LLC.
Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. According to IQVIA (IMS Health), Calcium Gluconate Injection USP, (100 mg/mL in 10 mL, 50 mL and 100 mL Vials) had US sales of approximately $71 million for the 12-month period ending March 2026.
